Stimulant Use Disorder - Contingency and Pharmacotherapy Options

Key Points

• Contingency management is the most strongly supported behavioral treatment for stimulant use disorder.
• There is no FDA-approved medication specifically for stimulant use disorder.
• Selected off-label pharmacotherapy can be considered based on stimulant type, comorbidity, and specialist judgment.
• Acute stimulant toxicity can cause hyperthermia, seizures, myocardial ischemia, stroke, arrhythmia, and rhabdomyolysis.
• Fentanyl contamination means naloxone access is relevant even for people who do not intentionally use opioids.
• Withdrawal can cause profound dysphoria and suicidality despite usually lacking the autonomic danger of alcohol withdrawal.
• Treat co-occurring opioid, alcohol, psychiatric, infectious, and social needs concurrently.
• Avoid punitive treatment structures that discharge patients for recurrence without attempting re-engagement.

Algorithm

1. Identify stimulant type, pattern, route, overdose history, coexposures, and current intoxication or withdrawal.
2. Assess temperature, cardiovascular and neurologic status, hydration, agitation, psychosis, and suicide risk.
3. Obtain symptom-directed ECG, troponin, CK, renal/electrolyte testing, glucose, pregnancy testing, and imaging.
4. Stabilize acute hyperthermia, agitation, seizures, ischemia, or opioid coexposure.
5. Offer contingency management and evidence-based psychosocial treatment.
6. Evaluate selected off-label pharmacotherapy according to comorbidity and patient preference.
7. Provide naloxone and harm-reduction services and treat co-occurring substance use disorders.
8. Track treatment engagement, stimulant use, sleep, mood, psychosis, housing, and functional recovery longitudinally.

Clinical Synopsis & Reasoning

Stimulant use disorder is diagnosed from a maladaptive pattern of stimulant use causing impaired control, social impairment, risky use, and/or pharmacologic consequences. History should specify methamphetamine, cocaine, prescription stimulant misuse, route, frequency, amount, binge pattern, sleep deprivation, injection risk, sexual risk, fentanyl exposure, and prior overdoses. Screen for depression, suicidality, psychosis, PTSD, ADHD, alcohol/opioid use disorder, and stimulant withdrawal. Withdrawal commonly produces fatigue, hypersomnia or insomnia, increased appetite, dysphoria, anhedonia, and craving; severe depression and suicidality require direct assessment.

Acute stimulant intoxication can produce severe sympathetic toxicity, agitation, hyperthermia, seizures, chest pain, aortic syndromes, myocardial ischemia, tachyarrhythmia, hypertension, stroke, rhabdomyolysis, and excited delirium-like presentations. Modern illicit stimulant supplies may contain fentanyl, so respiratory depression or unexplained sedation should trigger naloxone and opioid-overdose management. ECG, temperature, glucose, electrolytes, CK, troponin, renal function, pregnancy testing, and imaging are selected by symptoms. Psychosis that persists beyond expected intoxication/withdrawal requires evaluation for a primary psychotic disorder or prolonged stimulant-induced psychosis.

Treatment Strategy & Disposition

Contingency management has the strongest evidence among treatments for stimulant use disorder and should be a primary component of care when available. It provides tangible, timely reinforcement for treatment engagement or verified abstinence. Community reinforcement, CBT, and motivational interventions can complement contingency management. Treatment should also address housing, infectious disease, sexual health, trauma, and co-occurring opioid use because these factors strongly influence outcomes.

No medication is FDA approved specifically for stimulant use disorder. The ASAM/AAAP guideline supports consideration of selected off-label medications for some patients, including bupropion plus extended-release injectable naltrexone for methamphetamine use disorder in certain circumstances, and other options such as topiramate or mirtazapine depending on stimulant type and comorbidity, with modest evidence and specialist judgment. Naltrexone is inappropriate if the patient requires opioid analgesia or has current physiologic opioid dependence without appropriate initiation planning. If ADHD coexists, it should not be ignored, but controlled stimulant treatment requires careful diagnosis and monitoring. Harm reduction includes naloxone access, fentanyl test-strip education where legal/available, sterile injection supplies, hydration/cooling education, and avoiding solitary use.

Epidemiology / Risk Factors

• Methamphetamine and cocaine use contribute substantial cardiovascular, neurologic, psychiatric, infectious, and overdose morbidity.
• Illicit stimulant overdose deaths increasingly involve synthetic opioids in the drug supply.
• Stimulant use disorder commonly coexists with depression, PTSD, ADHD, and other substance use disorders.
• Housing instability and criminalization can interfere with treatment retention and should be addressed as practical clinical barriers.

Investigations

Care Components

Pharmacology

Prognosis / Complications

• Recovery is common but often nonlinear, with recurrence of use best treated as a signal to adjust care rather than terminate it.
• Psychosis, depression, sleep disturbance, and cognitive symptoms can persist for weeks after heavy use in some patients.
• Cardiovascular and cerebrovascular complications can cause permanent disability or death even in young patients.
• Retention in evidence-based behavioral treatment and treatment of co-occurring disorders improve long-term outcomes.

Patient Education / Counseling

• Provide naloxone and explain that fentanyl may be present even when the intended drug is methamphetamine or cocaine.
• Discuss avoiding solitary use, using smaller test doses, and accessing drug-checking or sterile-supply services when available.
• Warn about overheating, prolonged exertion, dehydration, chest pain, severe headache, seizures, or confusion as emergency symptoms.
• Frame recurrence of use as a reason to return to treatment rather than a reason for shame or discharge.
• Address sleep, nutrition, dental care, wound care, sexual health, and infectious-disease screening as part of recovery.

Notes

Stimulant use disorder treatment should not be organized around a false choice between abstinence and harm reduction. Contingency management can pursue abstinence while naloxone, sterile supplies, and safer-use counseling reduce mortality during the process of recovery. Similarly, co-occurring ADHD, depression, PTSD, or opioid use disorder should be treated rather than deferred until a patient achieves perfect stimulant abstinence.

Acute medical encounters are opportunities for treatment engagement. A patient discharged after stimulant-associated chest pain, psychosis, or rhabdomyolysis should leave with a specific addiction follow-up pathway, overdose-prevention resources, and management of co-occurring opioid exposure. Warm handoffs and rapid appointments are more effective than a generic instruction to “stop using.”

References

1. ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder — Link